Skip Navigation
Skip to contents

Science Editing : Science Editing

OPEN ACCESS
SEARCH
Search

Editorial policy

Page Path
HOME > For authors and reviewers > Editorial policy
For authors and reviewers
1. Copyright & License
2. Peer review policy
3. Data sharing policy
4. Data archiving policy
5. Preprint policy
6. Advertising policy

1. Copyright & License

All published papers become the permanent property of the Korean Council of Science Editors. Copyrights of all published materials are owned by the Korean Council of Science Editors. Permission must be obtained from the Korean Council of Science Editors for any commercial use of materials. Every author should sign the copyright transfer agreement forms (https://www.escienceediting.org/authors/copyright_transfer_agreement.php).

This is an Open Access journal distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted, distribution, and reproduction in any medium, provided the original work is properly cited.

2. Peer review policy

Science Editing has an online submission and peer review system at https://submit.escienceediting.org/.

Science Editing reviews all manuscripts received. A manuscript is first reviewed for its format and adherence to the aims and scope of the journal. If the manuscript meets these two criteria, it is dispatched to three investigators in the field with relevant knowledge.

Science Editing adopts double blind review, which means that the reviewers and authors cannot identify each others’ information. The authors’ names and affiliations are removed during peer review.

Assuming the manuscript is sent to reviewers, Science Editing waits to receive opinions from at least two reviewers. In addition, if deemed necessary, a review of statistics may be requested. The acceptance criteria for all papers are based on the quality and originality of the research and its scientific significance. Acceptance of the manuscript is decided based on the critiques and recommended decision of the reviewers.

An initial decision will normally be made within 4 weeks of receipt of a manuscript, and the reviewers’ comments are sent to the corresponding author by e-mail. The corresponding author must indicate the alterations that have been made in response to the reviewers’ comments item by item. Failure to resubmit the revised manuscript within 4 weeks of the editorial decision is regarded as a withdrawal. A final decision on acceptance/rejection for publication is forwarded to the corresponding author from the editor.

All manuscripts from editors, employees, or members of the editorial board are processed same to other unsolicited manuscripts. During the review process, submitters will not engage in the decision process. Editors will not handle their own manuscripts although they are commissioned ones.

We neither guarantee the acceptance without review nor very short peer review times for unsolicited manuscripts. Commissioned manuscripts also reviewed before publication.

3. Data sharing policy

Open data policy
For clarification on result accuracy and reproducibility of the results, raw data or analysis data will be deposited to a public repository, for example, Harvard Dataverse https://dataverse.harvard.edu/dataverse/) after acceptance of the manuscript. Therefore, submission of the raw data or analysis data is mandatory. If the data is already a public one, its URL site or sources should be disclosed. If data cannot be publicized, it can be negotiated with the editor. If there are any inquiries on depositing data, authors should contact the editorial office.

Clinical data sharing policy
This journal follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors” (https://doi.org/10.3346/jkms.2017.32.7.1051). As of July 1, 2018 manuscripts submitted to ICMJE journals that report the results of interventional clinical trials must contain a data sharing statement as described below. Clinical trials that begin enrolling participants on or after January 1, 2019 must include a data sharing plan in the trial's registration. The ICMJE's policy regarding trial registration is explained at https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record. All of the authors of research articles that deal with interventional clinical trials must submit data sharing plan of example 1 to 4 in Table 1. Based on the degree of sharing plan, authors should deposit their data after deidentification and report the DOI of the data and the registered site.

Table 1.   Examples of data sharing statements that fulfill these ICMJE requirements*

Element Example 1 Example 2 Example 3 Example 4
Will individual participant data be available (including data dictionaries)? Yes Yes Yes No
What data in particular will be shared? All individual participant data collected during the trial, after deidentification. Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). Not available
What other documents will be available? Study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code Study protocol, statistical analysis plan, analytic code Study protocol Not available
When will data be available (start and end dates)? Immediately following publication. No end date. Beginning at 3 months and ending at 5 years following the article publication. Beginning at 9 months and ending at 36 months following the article publication. Not applicable
With whom? Anyone who wishes to access the data. Researchers who provide a methodologically sound proposal. Investigators whose proposed use of the data has been approved by an independent review committee (“learned intermediary”) identified for this purpose. Not applicable
For what types of analyses? Any purpose To achieve aims in the approved proposal. For individual participant data meta-analysis. Not applicable
By what mechanism will data be made available? Data are available indefinitely at (link to be included). Proposals should be directed to xxx@yyy. To gain access, data requestors will need to sign a data access agreement. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Not applicable
Data are available for 5 years at a third-party website (link to be included). Information regarding submitting proposals and accessing data may be found at (link to be provided).

ICMJE = International Committee of Medical Journal Editors.
*These examples are meant to illustrate a range of, but not all, data sharing options.

4. Data archiving policy

It is accessible without barrier from Korea Citation Index (https://kci.go.kr) or National Library of Korea (http://nl.go.kr) in the event a journal is no longer published.

5. Preprint policy

A preprint can be defined as a version of a scholarly paper that precedes formal peer review and publication in a peer-reviewed scholarly journal. Science Editing allows authors to submit preprints to the journal. It is not treated as duplicate submission or duplicate publication. Science Editing recommends that authors disclose the existence of a preprint with its DOI in the letter to the editor during the submission process. Otherwise, a plagiarism check program may flag the results as containing excessive duplication. A preprint submission will be processed through the same peer review process as a usual submission. If a preprint is accepted for publication, the authors are recommended to update the information on the preprint site with a link to the published article in Science Editing, including the DOI at Science Editing. It is strongly recommended that authors cite the article in Science Editing instead of the preprint in their next submission to journals.

6. Advertising policy

Science Editing accepts advertisements on the following basis:

Eligibility of the advertised products or services
All products or services should be safe and reliable, and not cause any harm to the health and welfare of humans. Advertisements may promote information and technologies relevant for authors, editors, reviewers, and readers. Pharmaceutical products may also be considered.

Orders
Any individuals or organizations who are interested in advertising their products or services in the print copies of the journal or on its website are encouraged to contact the editorial office. The acceptance of advertisement will be discussed by the editorial board and will be ultimately approved by the publisher.

Advertisement fee
For one print copy issue, the advertisement price for one whole page is USD 1,000 (or KRW 1,000,000). If the advertisement is half a page, the price is reduced by half. For a quarter of the page, this price is reduced by one quarter. For banner advertisements on the website, the price is negotiable according to the duration of its exposure on the journal homepage. The price is usually greater than that for print copies.

Disclaimer
Liability: Neither the publisher nor the editors will be legally liable for advertisements presented in the journal. In addition, they cannot guarantee the accuracy, completeness, or usefulness of the information provided.
Endorsement: The publisher and the editors do not endorse any products or services that are advertised.
Disclaimer: Neither the publisher nor the authors will be legally liable for any of the content of advertisements, so readers must keep this in mind when reading or seeing advertisements.


Science Editing : Science Editing
TOP